期刊文献+

应用细胞凋亡抑制因子评估心力衰竭患者心肌细胞凋亡水平 被引量:14

The application of Apo 1/Fas to evaluate apoptosis of myocardial cells in patients with congestive heart failure
原文传递
导出
摘要 目的研究心力衰竭患者细胞凋亡抑制因子(Apo1/Fas)水平变化,评估衰竭心肌细胞凋亡状态。方法采取链霉亲和素生物素ELISA法测定60例心力衰竭患者和52例正常对照组血清Apo1/Fas,白细胞介素(IL)6和肿瘤坏死因子α(TNFα)水平,并测定心力衰竭患者左室射血分数(EF),了解EF变化与Apo1/Fas间的关系。结果心功能Ⅲ、Ⅳ级患者血清Apo1/Fas,TNFα显著高于对照组及心功能Ⅰ、Ⅱ级患者(P值<0.01);所有心功能不全患者血清IL6水平均明显高于对照组(P值<005和0.01),且心功能Ⅲ、Ⅳ级患者高于心功能Ⅰ、Ⅱ级患者(P值<0.05);EF>55%组患者血清Apo1/Fas水平显著高于EF>55%组患者(P值<0.01)。结论心力衰竭患者血清Apo1/Fas反映了衰竭心肌细胞凋亡状态。IL6和TNFα则在心肌细胞凋亡中起重要的免疫调控作用。 Objective To study the changes of serum level of Apo 1/Fas in patients with congestive heart failure (CHF) and evaluate apoptosis of failing myocardial cells. Methods Strepavidin Biotin ELISA was used to determine serum level of Apo 1/Fas, interleukin 6(IL 6) and tumor necrosis factor (TNFα) in 60 patients with CHF. Cardiac ejection fraction (EF)of the patients were measured by acusson 128XP/10 echocardiagraph. Results Serum levels of Apo 1/Fas and TNFα in class Ⅲ and Ⅳ patients with CHF were significantly higher than those in class Ⅰand Ⅱ( P <0.01). Serum levels of IL 6 in all the patients were obviously higher than those in controls ( P <0.05 and 0.01) and the levels in class Ⅲ and Ⅳ patients were significantly higher than those in class Ⅰ and Ⅱ ( P <0.05). Serum levels of Apo 1/Fas in patients with EF<55 percent were higher than in those with EF>55 percent ( P <0.05). Conclusion Serum level of Apo 1/Fas in patients with CHF reflects a state of apoptosis in failing myocardial cells. IL 6 and TNFα have important effects on immune regulation of myocardial cell apoptosis.
出处 《中华内科杂志》 CAS CSCD 北大核心 1999年第3期168-170,共3页 Chinese Journal of Internal Medicine
关键词 心力衰竭 充血性心力衰竭 细胞凋亡 抑制因子 Hears failure, congesting Apoptosis Apo 1/Fas
  • 相关文献

参考文献1

  • 1Cheng J,Science,1994年,263卷,1759页

同被引文献80

  • 1黄震华.比索洛尔在心力衰竭治疗中的应用[J].中国新药与临床杂志,2006,25(6):471-474. 被引量:19
  • 2汪芳,李一石,胡大一,柯元南,李天德,陆国平,吴宗贵,陆凤翔,陈君柱,伍卫,吴书林,樊朝美,边文彦,顼志敏,明广华,蒋文.比较比索洛尔与卡维地洛治疗充血性心力衰竭的多中心随机双盲开放平行对照临床研究[J].中国临床药理学杂志,2006,22(4):243-245. 被引量:23
  • 3心肌病诊断与治疗建议[J].中华心血管病杂志,2007,35(1):5-16. 被引量:568
  • 4[1]Lysuo PG, Lysko K, Webb CL, et al . Neuroprotective of carvedilol and a hydroxylated derivative[J]. Bioche Miche Mical Pharm, 1998,56:1654.
  • 5[2]Feuesrtein GZ, Bril A, Ruffolo RR, et al. Protective effect of carvedilol in the myocardium[J] .Am J Cardio, 1997,80(11 A) :41 L.
  • 6[3]Tendera M, Ochala A. Overview of the results of recent beta blocker trials [J]. Curr Opin Cardiol,2001,16(2): 180 - 185.
  • 7[5]Birks E J, Latif N, Owen V, et al. Quantitative myocardial cytokine expression and activation of the apoptotic pathway in patients who require left ventricular assist devices[J]. Circulation, 2001, 104(12 Suppl 1 ):1233- 1240.
  • 8[6]Packer M. Effect of carvedilol on the survival of patients with chronic heart failure[J]. Circulation, 1995,92(Suppl 1 ): 126 - 142.
  • 9[7]Bromme H J, Holtz. Apoptosis in the heart: when and why[J]. Mol Cell Biochem, 1996,163:261 - 275.
  • 10[1]Chobanian AV,Bakris GL,Black HR,et al.The Seventh Report of the Joint National Committee on Prevention,Detection,Evaluation,and Treatment of High Blood Pressure:the JNC 7 report.JAMA,2003,289(19):2560-2572.

引证文献14

二级引证文献78

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部